흉곽출구증후군(TOS) 시장 : 규모, 점유율, 성장률, 산업 분석, 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of thoracic outlet syndrome (TOS) Market

The global thoracic outlet syndrome (TOS) market is witnessing steady growth, driven by rising disease prevalence, increasing awareness, and the preference for pharmacologic management over surgical intervention. The market was valued at USD 227.4 million in 2025 and is projected to grow to USD 243.9 million in 2026, reaching USD 367.72 million by 2034, reflecting a CAGR of 5.27% over the forecast period. North America dominated the market in 2025 with a 32.5% share, supported by advanced healthcare infrastructure and a high prevalence of TOS among athletes and elderly populations.

Understanding Thoracic Outlet Syndrome (TOS)

Thoracic outlet syndrome is a condition resulting from compression of neurovascular structures in the thoracic outlet. It is linked to trauma, repetitive activity, and anatomical variations. Symptoms may include pain, numbness, and swelling, and can affect the nerves, veins, or arteries depending on the subtype: neurogenic TOS (nTOS), venous TOS, or arterial TOS.

Market Drivers

A key driver of market growth is the increasing adoption of pharmacologic management before surgical decompression. Physicians prefer medications to relieve symptoms and delay or avoid surgery, especially for neurogenic TOS. For instance, a 2022 Maastricht University study demonstrated the effectiveness of conservative therapy in patients with nTOS, reinforcing the role of drugs as first-line treatment. Additionally, product launches of off-label generic drugs, such as Sunshine Biopharma Inc.'s Gabapentin in June 2025, further expand treatment options and market reach.

Market Restraints and Challenges

A major restraint is the absence of FDA or EMA-approved drugs specifically for TOS. All available medications are off-label, which may limit physician confidence and restrict market expansion. Furthermore, the lack of standardized diagnostic criteria leads to frequent misdiagnosis, delaying treatment initiation. A 2023 study by the University of Gothenburg found that over 30% of nTOS cases were initially misdiagnosed, highlighting this challenge.

Opportunities

The development of targeted neuro-modulatory and anti-spasm agents represents a promising opportunity for market growth. These therapies aim to precisely relax hypertonic muscles and alleviate nerve pain more effectively than conventional NSAIDs or muscle relaxants. For example, a 2024 randomized controlled trial published in Muscle & Nerve Journal reported beneficial outcomes using Botox injections in nTOS patients, indicating potential for innovative therapeutics.

Market Segmentation

• By Drug Class: NSAIDs dominate the market due to their widespread use for pain and inflammation in neurogenic TOS, which accounts for 90% of total cases. Other drug classes include anticoagulants, thrombolytics, muscle relaxants, corticosteroids, and others.
• By Type: Neurogenic TOS holds the largest share, with 87.6% in 2025, reflecting its high prevalence. Venous TOS and arterial TOS represent smaller market shares but are projected to grow steadily, with venous TOS showing a CAGR of 4.67% over the forecast period.
• By Route of Administration: Oral medications dominate with 66.3% share in 2024, due to convenience and availability. Parenteral and other routes are expected to grow at a moderate pace of around 4.54% CAGR.
• By Distribution Channel: Retail pharmacies and drug stores are the leading distribution channels, projected to account for 53.2% in 2025, driven by easy accessibility and widespread availability of NSAIDs and other off-label drugs. Hospital pharmacies and online pharmacies are growing steadily.

Regional Insights

North America leads the global TOS market, with the U.S. market projected at USD 66.7 million in 2025. Europe follows, expected to reach USD 59.1 million in 2025, driven by rising disease prevalence and awareness campaigns, with Germany at USD 12.2 million, France USD 9.4 million, and the U.K. USD 10.4 million. Asia Pacific is the third-largest region, projected at USD 68.2 million in 2025, with India and China contributing USD 10.9 million and USD 16.7 million, respectively. Latin America and the Middle East & Africa are forecasted to show moderate growth, with valuations of USD 13.9 million and USD 5.9 million respectively in 2025.

Competitive Landscape

The TOS market is fragmented with major players including Bayer AG (Germany), Pfizer Inc. (U.S.), Bristol-Myers Squibb (U.S.), Sun Pharmaceutical Industries (India), Assertio Therapeutics (U.S.), Daiichi Sankyo (Japan), and Takeda Pharmaceutical (U.S.). These companies focus on expanding their product portfolios with branded and generic drugs and strengthening research and development initiatives. Key developments include Lupin's generic rivaroxaban launch in October 2025 and Sandoz's introduction of new rivaroxaban strengths in Germany in August 2025.

Conclusion

The global TOS market is poised for steady growth from 2025 to 2034. Rising disease prevalence, increased awareness programs, and the shift toward pharmacologic management before surgery are key drivers. While lack of approved drugs and standardized diagnostics pose challenges, innovations in targeted therapies and the expansion of off-label medications are expected to sustain market growth. North America continues to lead, followed by Europe and Asia Pacific, with opportunities for expansion in emerging regions through enhanced awareness and improved access to therapeutics.

Segmentation By Drug Class, Type, Route of Administration, Distribution Channel, and Region

By Drug Class * Anticoagulants

• Thrombolytics
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Muscle Relaxants
• Corticosteroids
• Others

By Type * Neurogenic TOS

• Venous TOS
• Arterial TOS

By Route of Administration * Oral

• Parenteral
• Others

By Distribution Channel * Hospital Pharmacies

• Retail Pharmacies & Drug Stores
• Online Pharmacies

By Region * North America (By Drug Class, Type, Route of Administration, Distribution Channel, and Country)

• U.S.
• Canada
• Europe (By Drug Class, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug Class, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug Class, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug Class, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Thoracic Outlet Syndrome, By Key Countries, 2025
• 4.2. Key Industry Developments (Launches, Mergers, Acquisitions, Partnerships, etc.)
• 4.3. Pipeline Analysis, By Key Players
• 4.4. Regulatory & Reimbursement Scenario, By Key Countries

5. Global Thoracic Outlet Syndrome (TOS) Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. Anticoagulants
  • 5.1.2. Thrombolytics
  • 5.1.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • 5.1.4. Muscle Relaxants
  • 5.1.5. Corticosteroids
  • 5.1.6. Others
• 5.2. Market Analysis, Insights and Forecast - By Type
  • 5.2.1. Neurogenic TOS
  • 5.2.2. Venous TOS
  • 5.2.3. Arterial TOS
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Oral
  • 5.3.2. Parenteral
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacies
  • 5.4.2. Retail Pharmacies & Drug Stores
  • 5.4.3. Online Pharmacies
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Thoracic Outlet Syndrome (TOS) Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. Anticoagulants
  • 6.1.2. Thrombolytics
  • 6.1.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • 6.1.4. Muscle Relaxants
  • 6.1.5. Corticosteroids
  • 6.1.6. Others
• 6.2. Market Analysis, Insights and Forecast - By Type
  • 6.2.1. Neurogenic TOS
  • 6.2.2. Venous TOS
  • 6.2.3. Arterial TOS
• 6.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.3.1. Oral
  • 6.3.2. Parenteral
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital Pharmacies
  • 6.4.2. Retail Pharmacies & Drug Stores
  • 6.4.3. Online Pharmacies
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Thoracic Outlet Syndrome (TOS) Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. Anticoagulants
  • 7.1.2. Thrombolytics
  • 7.1.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • 7.1.4. Muscle Relaxants
  • 7.1.5. Corticosteroids
  • 7.1.6. Others
• 7.2. Market Analysis, Insights and Forecast - By Type
  • 7.2.1. Neurogenic TOS
  • 7.2.2. Venous TOS
  • 7.2.3. Arterial TOS
• 7.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.3.1. Oral
  • 7.3.2. Parenteral
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital Pharmacies
  • 7.4.2. Retail Pharmacies & Drug Stores
  • 7.4.3. Online Pharmacies
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. Germany
  • 7.5.2. U.K.
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Thoracic Outlet Syndrome (TOS) Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. Anticoagulants
  • 8.1.2. Thrombolytics
  • 8.1.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • 8.1.4. Muscle Relaxants
  • 8.1.5. Corticosteroids
  • 8.1.6. Others
• 8.2. Market Analysis, Insights and Forecast - By Type
  • 8.2.1. Neurogenic TOS
  • 8.2.2. Venous TOS
  • 8.2.3. Arterial TOS
• 8.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.3.1. Oral
  • 8.3.2. Parenteral
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital Pharmacies
  • 8.4.2. Retail Pharmacies & Drug Stores
  • 8.4.3. Online Pharmacies
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Thoracic Outlet Syndrome (TOS) Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. Anticoagulants
  • 9.1.2. Thrombolytics
  • 9.1.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • 9.1.4. Muscle Relaxants
  • 9.1.5. Corticosteroids
  • 9.1.6. Others
• 9.2. Market Analysis, Insights and Forecast - By Type
  • 9.2.1. Neurogenic TOS
  • 9.2.2. Venous TOS
  • 9.2.3. Arterial TOS
• 9.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.3.1. Oral
  • 9.3.2. Parenteral
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital Pharmacies
  • 9.4.2. Retail Pharmacies & Drug Stores
  • 9.4.3. Online Pharmacies
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Thoracic Outlet Syndrome (TOS) Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug Class
  • 10.1.1. Anticoagulants
  • 10.1.2. Thrombolytics
  • 10.1.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • 10.1.4. Muscle Relaxants
  • 10.1.5. Corticosteroids
  • 10.1.6. Others
• 10.2. Market Analysis, Insights and Forecast - By Type
  • 10.2.1. Neurogenic TOS
  • 10.2.2. Venous TOS
  • 10.2.3. Arterial TOS
• 10.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.3.1. Oral
  • 10.3.2. Parenteral
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital Pharmacies
  • 10.4.2. Retail Pharmacies & Drug Stores
  • 10.4.3. Online Pharmacies
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
  • 11.2.1. Bayer AG
  • 11.2.2. Pfizer Inc.
  • 11.2.3. Bristol-Myers Squibb Company
  • 11.2.4. Sun Pharmaceutical Industries Ltd.
  • 11.2.5. Assertio Therapeutics, Inc.
  • 11.2.6. Daiichi Sankyo Co., Ltd.
  • 11.2.7. Takeda Pharmaceutical Company Limited